M&A Deal Summary

MedImmune Acquires AlphaCore Pharma

On April 3, 2013, MedImmune acquired life science company AlphaCore Pharma

Acquisition Highlights
  • This is MedImmune’s 3rd transaction in the Life Science sector.
  • This is MedImmune’s 3rd transaction in the United States.
  • This is MedImmune’s 1st transaction in Michigan.

M&A Deal Summary
Date 2013-04-03
Target AlphaCore Pharma
Sector Life Science
Buyer(s) MedImmune
Deal Type Add-on Acquisition

Target

AlphaCore Pharma

Ann Arbor, Michigan, United States
AlphaCore Pharma, an Ann Arbor, Michigan-based biotechnology company focused on the development of ACP-501, a recombinant human lecithin-cholesterol acyltransferase (LCAT) enzyme.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

MedImmune

Gaithersburg, Maryland, United States
Category Company
Founded 1988
Sector Medical Products
Employees2,000
DESCRIPTION

MedImmune strives to provide better medicines to patients, new medical options for physicians, rewarding careers to employees, and increased value to shareholders. Dedicated to advancing science and medicine to help people live better lives, the company is focused on the areas of infectious diseases, cancer and inflammatory diseases. With approximately 2,000 employees worldwide, MedImmune is headquartered in Maryland.

DEAL STATS #
Overall 3 of 6
Sector (Life Science) 3 of 6
Type (Add-on Acquisition) 3 of 5
State (Michigan) 1 of 1
Country (United States) 3 of 4
Year (2013) 1 of 4
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2005-09-14 Cellective Therapeutics

Gaithersburg, Maryland, United States

Cellective Therapeutics was a biopharmaceutical company focused on developing monoclonal antibodies for the treatment of oncology and autoimmune diseases such as B-cell lymphoma, Crohn?s disease and rheumatoid arthritis. The Company was founded in 2003 by Dr. Tom Tedder, Chairman of the Department of Immunology at Duke University, and based on technology licensed from Duke University and the Dana Farber Cancer Institute. Cellective was acquired by MedImmune in September of 2005.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2013-08-26 Amplimmune

Gaithersburg, Maryland, United States

Amplimmune, Inc. is a biologics company focused on developing novel therapeutics in cancer immunology.

Buy $500M
Mergr

Product

Company

Legal